In science you usually discover a condition or an issue first and then try to figure out why it occurs. Once you have figured whatthe causes are, only then would you propose a cure. In the case of A2M, the condition itself—A1 intolerance—has not been established, at all. Despite that, however, the company is marketing products that it claims are able to help alleviate it. What the company is doing a travesty. It is like spitting in the face of science. By chemistry alone, I am absolutely certain that the claims are BS. I can explain it to you all if you are all interested.
In science you usually discover a condition or an issue first...
-
- There are more pages in this discussion • 6,603 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.19 |
Change
-0.130(2.44%) |
Mkt cap ! $3.757B | |||
| Open | High | Low | Value | Volume |
| $5.26 | $5.29 | $5.19 | $21.70M | 4.165M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 11002 | $5.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.23 | 19654 | 8 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |